Elicio Therapeutics ($ELTX) Insider Trading & Smart Money Activity

Elicio Therapeutics, Inc. · Biotechnology · Latest filing Jun 18, 2026

Elicio Therapeutics, Inc. ($ELTX) has 4 analyst ratings on file.

Insider buyers (12 mo)
0
Insider sellers (12 mo)
0
Net insider $ (12 mo)
$0
Congress trades (12 mo)
0
13F moves on file
0
Analyst ratings on file
4

ELTX insider buying and selling by quarter

QuarterInsider buysInsider salesCongress buys / sales13F added / cut
Q1 2026 0 0 0 / 0 0 / 0
Q2 2026 0 0 0 / 0 0 / 0
Q3 2026 0 0 0 / 0 0 / 0
Q4 2026 0 0 0 / 0 0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All ELTX insider, congress, 13F and analyst activity

DateSourceWhoActionSharesValue / amount ΔOwn1W1M6MFilingStory
Analyst Ladenburg Thalmann Raises to buy PT $12 -2.6%-21.0% Read
Analyst HC Wainwright Reiterates to buy PT $23 +1.5%-25.5% Read
Analyst B. Riley Securities Reiterates to buy PT $27 -67.1%-75.7% —
Analyst B. Riley Securities Reiterates to buy PT $27 -67.1%-75.7% Read

1W / 1M / 6M = how ELTX moved from the trade or filing date.

Analyst ratings on ELTX

DateFirmActionRatingPrice target1W1M6MStory
Ladenburg Thalmann Raises buy $12 -2.6%-21.0% Read
HC Wainwright Reiterates buy $23 +1.5%-25.5% Read
B. Riley Securities Reiterates buy $27 -67.1%-75.7% —
B. Riley Securities Reiterates buy $27 -67.1%-75.7% Read

Other biotechnology stocks

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.

Get trade alerts by text